RLMD
Relmada Therapeutics, Inc.$4.43-0.01 (-0.11%)Prev Close$4.44·MCap$426.9M·P/E—·Vol1.61M·Yield—
▲
Buys (12M)
8
$4.03M
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$4.03M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Relmada Therapeutics, Inc. (RLMD) has been exclusively buying, with 8 insider purchases totaling $4.03M and 0 insider sales totaling $0.00. The most recent insider transaction was by Shenouda Maged (officer: Chief Financial Officer), who purchased $844.0K worth of shares on Sep 11, 2026. Relmada Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $426.9M.
RLMD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Shenouda Maged | officer: Chief Financial Officer | Buy | 200,000 | $4.22 | $844.0K | 1,000,000+25% |
| Sep 11, 2026 | TRAVERSA SERGIO | director, officer: Chief Executive Officer | Buy | 200,000 | $4.14 | $828.0K | 1,500,000 |
| Dec 12, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 11,665 | $4.12 | $48.1K | 0 |
| Dec 12, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 27,500 | $4.12 | $113.3K | 0 |
| Nov 5, 2025 | Ence Chuck | CAO and COO | Buy | 136,000 | $2.20 | $299.2K | 0 |
| Nov 5, 2025 | Kelly Paul Edward | Chief Operating Officer | Buy | 90,000 | $2.20 | $198.0K | 0 |
| Nov 5, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 500,000 | $2.20 | $1.10M0.7% OS | 0 |
| Nov 5, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 272,500 | $2.20 | $599.5K | 0 |
| Aug 26, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 265,976 | $0.67 | $178.1K | 0 |
| May 16, 2025 | Ence Chuck | CA and CO | Buy | 228,961 | $0.45 | $103.3K | 0 |
| May 16, 2025 | Kelly Paul Edward | Chief Operating Officer | Buy | 200,000 | $0.43 | $86.1K | 0 |
| May 16, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 200,000 | $0.49 | $97.2K | 0 |
| May 16, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 350,000 | $0.50 | $174.7K | 0 |
| Sep 11, 2024 | CASAMENTO CHARLES J | Director | Buy | 13,000 | $2.56 | $33.3K | 13,000 |
| Sep 11, 2024 | Kelly Paul Edward | Director | Buy | 25,000 | $2.59 | $64.8K | 212,295 |
| Sep 11, 2024 | Shenouda Maged | Chief Financial Officer | Buy | 53,432 | $2.80 | $149.7K | 88,335+153% |
| Sep 11, 2024 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 140,000 | $2.82 | $395.1K | 384,024+57% |
| Jan 31, 2024 | Ence Chuck | CA and CO | Buy | 38,970 | $3.87 | $150.9K | 38,970 |
| Jan 31, 2024 | Shenouda Maged | Chief Financial Officer | Buy | 32,675 | $3.85 | $125.7K | 34,903New Position |
| Jan 31, 2024 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 100,000 | $3.87 | $386.7K | 244,024+69% |
| May 24, 2023 | O'Gorman Cedric | Chief Medical Officer | Buy | 10,000 | $3.18 | $31.8K | 10,121New Position |
| Dec 12, 2022 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 55,250 | $2.10 | $115.8K | 144,024+62% |
| Jul 5, 2022 | TRAVERSA SERGIO | Chief Executive Officer | Sell | 29,767 | $18.80 | $559.6K | 101,690 |
| Apr 5, 2022 | CASAMENTO CHARLES J | Director | Sell | 3,300 | $29.00 | $95.7K | 16,500 |
| Apr 5, 2022 | Kelly Paul Edward | Director | Sell | 10,000 | $30.04 | $300.4K | 187,295 |
| Sep 24, 2021 | CASAMENTO CHARLES J | Director | Sell | 6,600 | $29.00 | $191.4K | 14,700-31% |
| Jul 16, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,300 | $31.54 | $104.1K | 5,854-36% |
| Jun 2, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $33.34 | $100.0K | 9,430 |
| May 5, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $38.22 | $114.6K | 9,950 |
| Apr 5, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $35.43 | $106.3K | 14,641 |
| Mar 11, 2021 | Kelly Paul Edward | Director | Sell | 5,000 | $35.71 | $178.6K | 168,907 |
| Mar 11, 2021 | TRAVERSA SERGIO | CEO | Sell | 10,000 | $35.48 | $354.8K | 93,937 |
| Mar 10, 2021 | Shenouda Maged | CFO | Sell | 10,000 | $35.45 | $354.5K | 12,128-45% |
| Mar 2, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $33.87 | $101.6K | 15,950 |
RLMD Insider Buying Activity
The following table shows recent insider purchases of Relmada Therapeutics, Inc. (RLMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Shenouda Maged | officer: Chief Financial Officer | Buy | 200,000 | $4.22 | $844.0K | 1,000,000+25% |
| Sep 11, 2026 | TRAVERSA SERGIO | director, officer: Chief Executive Officer | Buy | 200,000 | $4.14 | $828.0K | 1,500,000 |
| Dec 12, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 11,665 | $4.12 | $48.1K | 0 |
| Dec 12, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 27,500 | $4.12 | $113.3K | 0 |
| Nov 5, 2025 | Ence Chuck | CAO and COO | Buy | 136,000 | $2.20 | $299.2K | 0 |
| Nov 5, 2025 | Kelly Paul Edward | Chief Operating Officer | Buy | 90,000 | $2.20 | $198.0K | 0 |
| Nov 5, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 500,000 | $2.20 | $1.10M0.7% OS | 0 |
| Nov 5, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 272,500 | $2.20 | $599.5K | 0 |
| Aug 26, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 265,976 | $0.67 | $178.1K | 0 |
| May 16, 2025 | Ence Chuck | CA and CO | Buy | 228,961 | $0.45 | $103.3K | 0 |
| May 16, 2025 | Kelly Paul Edward | Chief Operating Officer | Buy | 200,000 | $0.43 | $86.1K | 0 |
| May 16, 2025 | Shenouda Maged | Chief Financial Officer | Buy | 200,000 | $0.49 | $97.2K | 0 |
| May 16, 2025 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 350,000 | $0.50 | $174.7K | 0 |
| Sep 11, 2024 | CASAMENTO CHARLES J | Director | Buy | 13,000 | $2.56 | $33.3K | 13,000 |
| Sep 11, 2024 | Kelly Paul Edward | Director | Buy | 25,000 | $2.59 | $64.8K | 212,295 |
| Sep 11, 2024 | Shenouda Maged | Chief Financial Officer | Buy | 53,432 | $2.80 | $149.7K | 88,335+153% |
| Sep 11, 2024 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 140,000 | $2.82 | $395.1K | 384,024+57% |
| Jan 31, 2024 | Ence Chuck | CA and CO | Buy | 38,970 | $3.87 | $150.9K | 38,970 |
| Jan 31, 2024 | Shenouda Maged | Chief Financial Officer | Buy | 32,675 | $3.85 | $125.7K | 34,903New Position |
| Jan 31, 2024 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 100,000 | $3.87 | $386.7K | 244,024+69% |
| May 24, 2023 | O'Gorman Cedric | Chief Medical Officer | Buy | 10,000 | $3.18 | $31.8K | 10,121New Position |
| Dec 12, 2022 | TRAVERSA SERGIO | Chief Executive Officer | Buy | 55,250 | $2.10 | $115.8K | 144,024+62% |
RLMD Insider Selling Activity
The following table shows recent insider sales of Relmada Therapeutics, Inc. (RLMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 5, 2022 | TRAVERSA SERGIO | Chief Executive Officer | Sell | 29,767 | $18.80 | $559.6K | 101,690 |
| Apr 5, 2022 | CASAMENTO CHARLES J | Director | Sell | 3,300 | $29.00 | $95.7K | 16,500 |
| Apr 5, 2022 | Kelly Paul Edward | Director | Sell | 10,000 | $30.04 | $300.4K | 187,295 |
| Sep 24, 2021 | CASAMENTO CHARLES J | Director | Sell | 6,600 | $29.00 | $191.4K | 14,700-31% |
| Jul 16, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,300 | $31.54 | $104.1K | 5,854-36% |
| Jun 2, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $33.34 | $100.0K | 9,430 |
| May 5, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $38.22 | $114.6K | 9,950 |
| Apr 5, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $35.43 | $106.3K | 14,641 |
| Mar 11, 2021 | Kelly Paul Edward | Director | Sell | 5,000 | $35.71 | $178.6K | 168,907 |
| Mar 11, 2021 | TRAVERSA SERGIO | CEO | Sell | 10,000 | $35.48 | $354.8K | 93,937 |
| Mar 10, 2021 | Shenouda Maged | CFO | Sell | 10,000 | $35.45 | $354.5K | 12,128-45% |
| Mar 2, 2021 | CASAMENTO CHARLES J | Director | Sell | 3,000 | $33.87 | $101.6K | 15,950 |
RLMD Insiders
TRAVERSA SERGIO
director, officer: Chief Executive Officer
Bought $2.79MSold $914.4K
10 tradesLast: Sep 11, 2026
Similar Stocks to RLMD
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B